VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm

LOS ANGELES, Oct. 28, 2024

Investors who purchased the Company's securities between August 9, 2022, and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.       

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Verve failed to disclose the circumstances under which its Heart-1 Phase 1b clinical trial (the "Heart-1 Trial") of VERVE-101 would be halted. The Company overstated the benefits of its proprietary lipid nanoparticle (LNP) delivery system. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Verve, investors suffered damages.